Hyperlipoproteinemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Hardik Patel (talk | contribs) No edit summary |
Hardik Patel (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
===Medical Therapy in Children and Adolescents=== | ===Medical Therapy in Children and Adolescents=== | ||
*[[Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents | Drug therapy]] | *[[Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents | Drug therapy]] | ||
**[[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] | **[[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] | ||
| Line 14: | Line 13: | ||
===[[Hypertriglyceridemia medical therapy | Pharmacotherapy]]=== | ===[[Hypertriglyceridemia medical therapy | Pharmacotherapy]]=== | ||
* [[Omega-3 fatty acids]] | * [[Omega-3 fatty acids]] | ||
===Trial supportive data=== | ===Trial supportive data=== | ||
=====[[Niacin AIM HIGH study | AIM HIGH study]]===== | =====[[Niacin AIM HIGH study | AIM HIGH study]]===== | ||
Revision as of 19:54, 26 October 2012
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]